Iron plays an important role in maintaining cell survival, with normal iron trafficking known to be regulated by the ceruloplasmin-transferrin (Cp-Tf) antioxidant system. Disruption to this system is thought to be detrimental to normal brain function.
Objective:
To determine whether an imbalance of iron and the proteins involved in its metabolism (ceruloplasmin and transferrin) are linked to Alzheimer’s disease (AD) and to the expression of amyloid-beta (Aβ) peptide 1–42 (Aβ1–42), which is a major species of Aβ, and the most toxic.
Methods:
We evaluated the concentrations of iron, calcium, magnesium, and Aβ1–42 in the cerebrospinal fluid (CSF) of patients with AD and cognitively normal controls. Correlations between the components of the Cp-Tf antioxidant system in plasma were studied to determine the role of peripheral blood in the onset and/or development of AD. We used commercial ELISA immunoassays to measure Aβ1–42, immunoturbidimetry to quantify ceruloplasmin and transferrin, and colorimetry to quantify iron, calcium, and magnesium.
Results:
We found that the AD group had lower CSF concentrations of Aβ1–42 (p < 0.001) and calcium (p < 0.001), but a higher CSF concentration of iron (p < 0.001). Significantly lower plasma concentrations of ceruloplasmin (p = 0.003), transferrin (mean, p < 0.001), and iron (p < 0.001) were observed in the AD group than in cognitively normal adults. Moreover, we found a strong interdependence between most of these components.
Conclusion:
Iron dyshomeostasis has a crucial role in the onset of AD and/or its development. Correcting metal misdistribution is an appealing therapeutic strategy for AD.
Crous-BouM, MinguillónC, GramuntN, MolinuevoJ (2017) Alzheimer’s disease prevention: From risk factors to early intervention. Alzheimers Res Ther9, 71.
2.
ScheltensP, BlennowK, BretelerMM, de StrooperB, FrisoniGB, SallowayS, Van der FlierWM (2016) Alzheimer’s disease. Lancet388, 505–517.
3.
RossorMN, FoxNC, MummeryCJ, SchottJM, WarrenJD (2010) The diagnosis of young-onset dementia. Lancet Neurol9, 793–806.
4.
ListaS, O’BryantSE, BlennowK, DuboisB, HugonJ, ZetterbergH, HampelH (2015) Biomarkers in sporadic and familial Alzheimer’s disease. J Alzheimers Dis47, 291–317.
5.
BatemanRJ, AisenPS, De StrooperB, FoxNC, LemereCA, RingmanJM, SallowayS, SperlingRA, WindischM, XiongC (2011) Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther3, 1.
6.
Van DuijnCM, de KnijffP, CrutsM, WehnertA, HavekesLM, HofmanA, Van BroeckhovenC (1994) Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer’s disease. Nat Genet7, 74–78.
7.
SaundersAM, StrittmatterWJ, SchmechelD, George-HyslopPH, Pericak-VanceMA, JooSH, RosiBL, GusellaJF, Crapper-MacLachlanDR, AlbertsMJ, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology43, 1467–1472.
SelkoeDJ (1994) Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci17, 489–517.
14.
FerreiraIL, ResendeR, FerreiroE, RegoAC, PereiraCF (2010) Multiple defects in energy metabolism in Alzheimer’s disease. Curr Drug Targets11, 1193–1206.
15.
Alzheimer’s Association (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement12, 459–509.
16.
GiorgioM, TrineiM, MigliaccioE, PelicciPG (2007) Hydrogen peroxide: A metabolic by-product or a common mediator of ageing signals?Nat Rev Mol Cell Biol8, 722–728.
17.
LiptonSA (2007) Pathologically activated therapeutics for neuroprotection [published correction appears in Nat Rev Neurosci 8(11), 2p following 903]. Nat Rev Neurosci8, 803–808.
18.
GreenoughMA, CamakarisJ, BushAI (2013) Metal dyshomeostasis and oxidative stress in Alzheimer’s disease. Neurochem Int62, 540–555.
19.
ButterfieldDA, ReedT, SultanaR (2011) Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer’s disease. Free Radic Res45, 59–72.
20.
RavenEP, LuPH, TishlerTA, HeydariP, BartzokisG (2013) Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer’s disease detected in vivo with magnetic resonance imaging. J Alzheimers Dis37, 127–136.
21.
ConnorJR, SnyderBS, BeardJL, FineRE, MufsonEJ (1992) Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer’s disease. J Neurosci Res31, 327–335.
22.
American Psychiatric Association (1994) DSM-IV. Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, DC.
23.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
24.
RifaiN, KingME, MalekpourA, SmithJ, LawsonJ (1986) Immunoturbidimetric assay of transferrin: Effect of iron and need for serum blanks. Clin Biochem19, 31–34.
25.
GosriwatanaI, LorealO, LuS, BrissotP, PorterJ, HiderRC (1999) Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem273, 212–220.
26.
McDermottJ A, HuberC T, OsakiS, FriedenE (1968) Role of iron in the oxidase activity of ceruloplasmin. Biochim Biophys Acta151, 541–557.
27.
DaviesMJ (2005) The oxidative environment and protein damage. Biochim Biophys Acta1703, 93–109.
28.
ChevionM (1988) A site-specific mechanism for free radical induced biological damage: The essential role of redox-active transition metals. Free Radic Biol Med5, 27–37.
29.
StohsSJ, BagchiD (1995) Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med18, 321–336.
30.
AshrafA, AshtonNJ, ChatterjeeP, GoozeeK, ShenK, FrippJ, AmesD, RoweC, MastersCL, VillemagneV, HyeA, MartinsRN, So PW; AIBL (2020) Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology. Alzheimers Res Ther12, 72.
31.
PatelBN, DunnRJ, JeongSY, ZhuQ, JulienJP, DavidS (2002) Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci22, 6578–6586.
32.
DaviesKJ, DelsignoreME, LinSW (1987) Protein damage and degradation by oxygen radicals II Modification of amino acids. J Biol Chem262, 9902–9907.
33.
SlaterTF (1984) Free-radical mechanisms in tissue injury. Biochem J222, 1–15.
34.
HareDJ, DoeckeJD, FauxNG, RembachA, VolitakisI, FowlerCJ, GrimmR, DoblePA, ChernyRA, MastersCL, BushAI, RobertsBR (2015) Decreased plasma iron in Alzheimer’s disease is due to transferrin desaturation. ACS Chem Neurosci6, 398–402.
35.
VuralH, DemirinH, KaraY, ErenI, DelibasN (2010) Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer’s disease. J Trace Elem Med Biol24, 169–173.
FlemingJ, JoshiJG (1988) Ferritin: Isolation of aluminumferritin complex from brain [published correction appears in Proc Natl Acad Sci U S A 85(11), 3786]. Proc Natl Acad Sci U S A84, 7866–7870.
38.
JellingerK, PaulusW, Grundke-IqbalI, RiedererP, YoudimMB (1990) Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm Park Dis Dement Sect2, 327–340.
39.
FischerP, GötzME, DanielczykW, GsellW, RiedererP (1997) Blood transferrin and ferritin in Alzheimer’s disease. Life Sci60, 2273–2278.
AbbottNJ, PatabendigeAA, DolmanDE, YusofSR, BegleyDJ (2010) Structure and function of the blood–brain barrier. Neurobiol Dis37, 13–25.
42.
MoosT, OatesPS, MorganEH (1998) Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency. J Comp Neurol398, 420–430.
43.
TaylorEM, CroweA, MorganEH (1991) Transferrin and iron uptake by the brain: Effects of altered irons tatus. J Neurochem57, 1584–1592.
44.
WangCY, JenkitkasemwongS, DuarteS, SparkmanBK, ShawkiA, MackenzieB, KnutsonMD (2012) ZIP8 is an iron and zinc transporter whose cell-surface expression is up-regulated by cellular iron loading. J Biol Chem287, 34032–34043.
45.
Van RaaijSEG, SraiSKS, SwinkelsDW, van SwelmRPL (2019) Iron uptake by ZIP8 and ZIP14 in human proximal tubular epithelial cells. Biometals32, 211–226.
46.
MoosT, MorganEH (2003) The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain. J Neurochem88, 233–245.
47.
MillsE, DongXP, WangF, XuH (2010) Mechanisms of brain iron transport: Insight into neurodegeneration and CNS disorders. Future Med Chem2, 51–64.
48.
SkjørringeT, BurkhartA, JohnsenKB, MoosT (2015) Divalent metal transporter 1 (DMT1) in the brain: Implications for a role in iron transport at the blood-brain barrier and neuronal and glial pathology. Front Mol Neurosci8, 19.
49.
KuhlmannCR, GerigkM, BenderB, CloshenD, LessmannV, LuhmannHJ (2008) Fluvastatin prevents glutamate-induced blood-brain-barrier disruption in vitro. Life Sci82, 1281–1287.
50.
ReijerkerkA, KooijG, van der PolSMA, LeyenT, LakemanK, van het Hof, VivienD, de VriesHE (2010) The NR1 subunit of NMDA receptor regulates monocyte transmigration through the brain endothelial cell barrier. J Neurochem113, 447–453.
51.
HullinR, Singer-LahatD, FreichelM, BielM, DascalN, HofmannF, Flockerzi V Calcium channel beta subunit heterogeneity: Functional expression of cloned cDNA from heart (1992) Calcium channel beta subunit heterogeneity: Functional expression of cloned cDNA from heart, aorta and brain. EMBO J11, 885–890.
52.
JeongS Y, DavidS (2006) Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci26, 9810–9819.
53.
DongX,
GaoW,
ShaoT,
XieH,
BaiJ,
ZhaoJ,
ChaiX (2015) Age-related changes of brain iron load changes in the frontal cortex in APPswe/PS1ΔE9 transgenic mouse model of Alzheimer’s disease. J Trace Elem Med Biol30, 118–123.
CunninghamC, WilcocksonDC, CampionS, LunnonK, PerryVH (2005) Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci25, 9275–9284.
56.
CacquevelM, LebeurrierN, ChéenneS, VivienD (2004) Cytokines in neuroinflammation and Alzheimer’s disease. Curr Drug Targets5, 529–534.
57.
HallidayG, RobinsonSR, ShepherdC, KrilJ (2000) Alzheimer’s disease and inflammation: A review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol27, 1–8.
58.
DasTK, WatiMR, Fatima-ShadK (2015) Oxidative stress gated by Fenton and Haber Weiss reactions and its association with Alzheimer’s disease. Arch Neurosci2, e60038.
59.
PelizzoniI, MaccoR, MoriniMF, ZacchettiD, GrohovazF, CodazziF (2011) Iron handling in hippocampal neurons: Activity-dependent iron entry and mitochondria-mediated neurotoxicity. Aging Cell10, 172–183.
60.
XuX, PinS, GathinjiM, FuchsR, HarrisZ (2004) Aceruloplasminemia: An inherited neurodegenerative disease with impairment of iron homeostasis. Ann N Y Acad Sci1012, 299–305.
61.
BaumannBH, ShuW, SongY, SimpsonEM, Lakhal-LittletonS, DunaiefJL (2019) Ferroportin-mediated iron export from vascular endothelial cells in retina and brain. Exp Eye Res187, 107728.
62.
AytonS, FauxNG, BushA (2015) Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE. Nat Commun6, 6760.
63.
SubhashMN, PadmashreeTS, SrinivasKN, SubbakrishnaDK, ShankarSK (1991) Calcium and phosphorus levels in serum and CSF in dementia. Neurobiol Aging12, 267–269.
64.
CheahJH, KimSF, HesterLD, ClancyKW, PattersonSE3rd, PapadopoulosV, SnyderSH (2006) NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron51, 431–440.
65.
AlbensiBC (2007) The NMDA receptor/ion channel complex: A drug target for modulating synaptic plasticity and excitotoxicity. Curr Pharm Des13, 3185–3194.
66.
NeuhausW, FreidlM, SzkokanP, BergerM, WirthM, WinklerJ, GaborF, PiflC, NoeCR (2011) Effects of NMDA receptor modulators on a blood–brain barrier in vitro model. Brain Res1394, 49–61.
67.
SattlerR, CharltonMP, HafnerM, TymianskiM (1998) Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J Neurochem71, 2349–2364.
68.
MuñozP, ZavalaG, CastilloK, AguirreP, HidalgoC, NúñezMT (2006) Effect of iron on the activation of the MAPK/ERK pathway in PC12 neuroblastoma cells. Biol Res39, 189–190.
69.
HidalgoC, NúñezMT (2007) Calcium, iron and neuronal function. IUBMB Life59, 280–285.
70.
AndreasenN, HesseC, DavidssonP, MinthonL, WallinA, WinbladB, VandersticheleH, VanmechelenE, BlennowK (1999) Cerebrospinal fluid β-amyloid (1-42) in Alzheimer disease: Differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol56, 673–680.
71.
MehtaPD, PirttiläT, MehtaSP, SersenEA, AisenPS, WisniewskiHM (2000) Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol57, 100–105.
72.
GoodmanL (1953) Alzheimer’s disease: A clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Ment Dis118, 97–130.
73.
CohenSI, LinseS, LuheshiLM, HellstrandE, WhiteDA, RajahL, OtzenDE, VendruscoloM, DobsonCM, KnowlesTP (2013) Proliferation of amyloid- 42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A110, 9758–9763.
74.
DuceJA, TsatsanisA, CaterMA, JamesSA, RobbE, WikheK, LeongSL, PerezK, JohanssenT, GreenoughMA, ChoHH, GalatisD, MoirRD, MastersCL, McLeanC, TanziRE, CappaiR, BarnhamKJ, CiccotostoGD, RogersJT, BushAI (2010) Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell142, 857–867.
75.
AbramovAY, CanevariL, DuchenMR (2004) Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. Biochim Biophys Acta1742, 81–87.
76.
LeeDG, ParkJ, LeeHS, LeeSR, LeeDS (2016) Iron overload-induced calcium signals modulate mitochondrial fragmentation in HT-22 hippocampal neuron cells. Toxicology365, 17–24.
77.
Crapper McLachlanDR, DaltonAJ, KruckTP, BellMY, SmithWL, KalowW, AndrewsDF (1991) Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet337, 1304–1308.
78.
PhaniendraA, JestadiDB, PeriyasamyL (2015) Free radicals: Properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem30, 11–26.
